What is HC Wainwright’s Estimate for Surrozen Q1 Earnings?

Surrozen, Inc. (NASDAQ:SRZN) – Stock analysts at HC Wainwright lifted their Q1 2025 EPS estimates for Surrozen in a report released on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($1.09) for the quarter, up from their previous forecast of ($2.71). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen’s Q2 2025 earnings at ($1.07) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($4.22) EPS, FY2026 earnings at ($4.63) EPS, FY2027 earnings at ($5.50) EPS, FY2028 earnings at ($6.53) EPS and FY2029 earnings at ($7.15) EPS.

Separately, Guggenheim raised Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price for the company in a report on Friday, January 3rd.

Surrozen Stock Performance

NASDAQ:SRZN opened at $9.80 on Monday. The business’s fifty day moving average is $11.31 and its 200 day moving average is $11.10. The firm has a market cap of $31.85 million, a price-to-earnings ratio of -0.45 and a beta of 0.69. Surrozen has a 52-week low of $6.00 and a 52-week high of $18.17.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Monday, March 31st. The company reported ($9.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.54) by ($6.56). The business had revenue of $0.66 million for the quarter.

Hedge Funds Weigh In On Surrozen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in shares of Surrozen by 26.1% in the 4th quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock valued at $321,000 after acquiring an additional 4,630 shares in the last quarter. Nantahala Capital Management LLC raised its stake in Surrozen by 4.7% in the fourth quarter. Nantahala Capital Management LLC now owns 196,023 shares of the company’s stock valued at $2,813,000 after purchasing an additional 8,817 shares in the last quarter. Stonepine Capital Management LLC raised its stake in Surrozen by 24.7% in the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock valued at $1,969,000 after purchasing an additional 27,200 shares in the last quarter. Trustees of Columbia University in the City of New York bought a new stake in Surrozen during the fourth quarter valued at approximately $688,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Surrozen in the 4th quarter worth approximately $928,000. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Surrozen

In other news, major shareholder Group Gp Lp Column III purchased 1,034,482 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average price of $11.60 per share, with a total value of $11,999,991.20. Following the completion of the acquisition, the insider now owns 795,411 shares in the company, valued at $9,226,767.60. This trade represents a -432.71 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 43.50% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.